SCHEMBL1963192

SCHEMBL1963192

CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OCCCCC(=O)O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.81
MAPK1 P28482 4/20 0.70
MEN1 O00255 3/20 0.70
GMNN O75496 3/20 0.70
LMNA P02545 3/20 0.70
BLM P54132 3/20 0.70
KMT2A Q03164 3/20 0.70
NPSR1 Q6W5P4 3/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
PRKD3 O94806 1/20 0.70
PRKCG P05129 1/20 0.70
PRKCB P05771 1/20 0.70
PRKCA P17252 1/20 0.70
PRKCH P24723 1/20 0.70
AKT1 P31749 1/20 0.70
PRKCI P41743 1/20 0.70
PRKCE Q02156 1/20 0.70
PRKCQ Q04759 1/20 0.70
PRKCZ Q05513 1/20 0.70
PRKCD Q05655 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2231559 1.00 RECQL (0.81) RECQLMAPK1MEN1GMNNLMNA
Vb-201 SCHEMBL14322398 1.00 RECQL (0.81) RECQLMAPK1MEN1GMNNLMNA
SCHEMBL2232585 1.00 RECQL (0.81) RECQLMAPK1MEN1GMNNLMNA
Vb-201 SCHEMBL2071110 1.00 RECQL (0.81) RECQLMAPK1MEN1GMNNLMNA
SCHEMBL704033 1.00 RECQL (0.81) RECQLMAPK1MEN1GMNNLMNA
SCHEMBL20143296 1.00 RECQL (0.81) RECQLMAPK1MEN1GMNNLMNA
SCHEMBL704034 1.00 RECQL (0.81) RECQLMAPK1MEN1GMNNLMNA
Vb-201 SCHEMBL2071230 1.00 RECQL (0.81) RECQLMAPK1MEN1GMNNLMNA
SCHEMBL2232633 1.00 RECQL (0.81) RECQLMAPK1MEN1GMNNLMNA
SCHEMBL703690 1.00 RECQL (0.81) RECQLMAPK1MEN1GMNNLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206206-B2 Oxidized lipid compounds and uses thereof VASCULAR BIOGENICS LTD. (IL) 2015-12-08 US disclosed
EP-2826369-A2 Oxidized lipid compounds and uses thereof Vascular Biogenics Ltd. (IL) 2015-01-21 EP disclosed
EP-2826370-A2 Oxidized lipid compounds and uses thereof Vascular Biogenics Ltd. (IL) 2015-01-21 EP disclosed
EP-2348866-B1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD (IL) 2015-01-07 EP disclosed
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof VASCULAR BIOGENICS LTD. (IL) 2013-08-08 US disclosed
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2011-08-25 US disclosed
EP-2348866-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF Vascular Biogenics Ltd. (IL) 2011-08-03 EP disclosed
WO-2010052718-A9 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2011-06-16 WO disclosed
WO-2010052718-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof LPO, GPX4, ALOX15B RECQL 4132/4885MAPK1 4229/4885MEN1 4782/4885
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF LPO, GPX4, ALOX15B RECQL 4132/4885MAPK1 4229/4885MEN1 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.